FDA Approval of Trifluridine and Tipiracil With Bevacizumab for Patients With Previously Treated Metastatic Colorectal Cancer

The FDA has approved trifluridine and tipiracil plus bevacizumab for the treatment of patients with metastatic colorectal cancer who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Access the full article to read more here.